We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.

Delisted

ITCI was delisted on the 1st of April, 2025.

35 hedge funds and large institutions have $201M invested in Intra-Cellular Therapies Inc. in 2014 Q1 according to their latest regulatory filings, with 35 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
35
Holders Change
+35
Holders Change %
% of All Funds
1.01%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
35
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
EEG
26
E.E. Geduld
$364K +$362K +20,030 New
SCA
27
SAC Capital Advisors
Connecticut
$348K +$346K +19,139 New
Charles Schwab
28
Charles Schwab
California
$346K +$343K +18,996 New
Millennium Management
29
Millennium Management
New York
$287K +$285K +15,781 New
State Street
30
State Street
Massachusetts
$278K +$276K +15,300 New
BIT
31
BlackRock Institutional Trust
California
$111K +$110K +6,094 New
ST
32
Stifel Trust
Missouri
$46K +$45.1K +2,500 New
U
33
UBS
Switzerland
$33K +$33.3K +1,842 New
TRCT
34
Tower Research Capital (TRC)
New York
$11K +$10.7K +593 New
Barclays
35
Barclays
United Kingdom
$2K +$1.8K +100 New

ITCI Hedge Fund Activity: Q1 2014 in Review

35 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2014, worth a combined $201M.

Buyers outnumbered sellers: 35 funds opened new ITCI positions and 0 closed out — a net gain of 35 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $79.1M.

  • 35 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2014, up from 0 in Q4 2013.
  • Funds reported $201M of Intra-Cellular Therapies Inc. stock for Q1 2014.
  • 35 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2014 and 0 closed out, a net change of +35 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2014 was Fidelity Investments, an estimated $79.1M added.

Based on aggregated 13F filings for Q1 2014.